Kurser indlæses...
Prognose
| Køb |
1 |
| Behold |
0 |
| Sælg |
0 |
Diskussioner i communityet
Der er endnu ingen diskussion om dette aktiv.
Start diskussionNyheder Til nyhedsfeedet
Almirall raises EBITDA sharply; biologics sales drive growth
Almirall reports H1 2026 EBITDA of €150.7 million (+23.7%) and net sales of €602.7 million (+7.5%), largely meeting or exceeding expectations. The growth was driven mainly by biologics: Ebglyss reached €84.5 million in sales (+88.2%) and Ilumetri €125.2 million (+10.5%), while the dermatology business in Europe grew by 18.1%. Management confirms the full-year guidance (net sales +9–12%, EBITDA €270–290 million); net income of €39.6 million was slightly below consensus and Ebglyss’s growth slowed in Q2, which dampened the share price recovery. » Mere på de.investing.com
Almirall reports mixed Q1 results: net revenue slightly below forecast, EBITDA beats
Almirall reported Q1 net revenue of €291.0m (consensus €293.4m) and total revenues of €292.4m, slightly below expectations. Profitability was robust: EBITDA €67.5m (consensus €66.7m), EBIT €30.0m (consensus €29.3m), while net profit of €15.3m missed the consensus of €19.1m, weighed down by higher net financial expenses and a revaluation of an equity swap. The dermatology business grew 16.3% to €179.7m, driven by Ebglyss (€41.9m) and Ilumetri (€61.6m). Almirall confirmed its full-year outlook (net revenue €1,208–1,241m, EBITDA €270–290m) and reported a bispecific antibody candidate entering Phase I studies. » Mere på de.investing.com
Almirall achieves over €1.1bn revenue in 2025 for first time thanks to biologics
Almirall reports net sales of €1,108.1m for fiscal 2025 (+12.4%) and an EBITDA of €232.9m, driven by strong sales of the biologics Ilumetri and Ebglyss in Europe. Ilumetri generated €234.4m, Ebglyss grew to €110.8m, while the US business suffered from competitive pressure and negative currency effects. For 2026 management expects revenue growth of 9–12% and an EBITDA of €270–290m; medium-term, Almirall aims for a double-digit CAGR through 2030 and an EBITDA margin around 25%. The balance sheet remains solid with a net leverage of 0.0x, but the stock fell about 1.56% after the announcement. » Mere på de.investing.com
Almirall SA raises net sales to EUR 1.108 billion, stock falls after earnings call
Almirall SA reported for 2025 a net sales increase of 12.4% to EUR 1.108 billion and an EBITDA of EUR 233 million (+21%). Despite the record figures, the share price fell 1.56% to USD 13.22, weighed down by a weakening performance in the US market and negative currency effects. Management emphasizes the product pipeline and expects further sales growth, but sees risks from margin pressure due to higher licensing fees and intense competition. » Mere på de.investing.com
Almirall: no price stabilization for €250m bond
J.P. Morgan SE said that no price-stabilizing measures were taken during the stabilization period for Almirall’s recent bond issuance of €250 million. The senior, unsecured bonds have a term of 5.5 years, are callable for the first time after two years, and were issued at 100% of par. The securities are listed on the Luxembourg Stock Exchange; J.P. Morgan acted as stabilization coordinator, with BNP Paribas, BBVA, BofA Securities, CaixaBank and Santander involved as stabilization managers. » Mere på de.investing.com
Historisk udbytte Udbytte
Alle nøgletal for udbytte Alle nøgletalVirksomhedstal
| (EUR) | september 2026 | YoY |
|---|---|---|
| Omsætning | 287,98 mio. | 10,66 % |
| Bruttofortjeneste | 110,63 mio. | 21,37 % |
| Nettoresultat | 13,75 mio. | 9,78 % |
| EBITDA | 85,08 mio. | 29,87 % |
Fundamentale data
| Nøgletal | Værdi |
|---|---|
Markedsværdi | 2,33 mia. € |
Antal aktier | 217,78 mio. |
Højeste/laveste i 52 uger | 13,98 € - 9,81 € |
Udbytteafkast | 1,75 % |
Udbytte TTM | 0,19 € |
Beta | 0,17 |
P/E (PE Ratio) | 31,81 |
PEG (PEG Ratio) | 0,45 |
K/I (PB Ratio) | 1,51 |
P/S (PS Ratio) | 1,62 |
Virksomhedsprofil
Almirall, S.A., et biofarmaceutisk selskab, beskæftiger sig med forskning, udvikling, fremstilling og salg af medicin til hudsundhed i Europa, USA og internationalt. Selskabet tilbyder sine produkter til dermatologiske sygdomme, herunder aktinisk keratose, atopisk dermatitis, androgen alopeci, psoriasis, onykomykose, onkodermatologi, acne og sjældne indikationer, samt til kardiovaskulære, muskel- og skeletsystemet, luftvejene og nervesystemet; fordøjelseskanalen og stofskiftet; antiinfektiva til systemisk brug; urogenitalsystemet og kønshormoner; immunstimulerende midler og systemiske hormonpræparater. Dets produkter omfatter Ilumetri, Solaraze, Actikerall, Ciclopoli, Skilarence, Aczone, Decoderm, Cordran Tape, Azelex, Klisyri, Tazorac, Seysara, Veltin, Almax, Ebastel, Sativex, Crestor og Efficib/Tesavel. Almirall, S.A. har samarbejds- og partneraftaler med Tyris Therapeutics, BIOMAP, University of Dundee, Kaken Pharmaceutical Co Ltd., Ichnos Sciences Inc., Universidad Carlos III de Madrid og MEDINA Foundation, 23andMe, Inc., HitGen Ltd., WuXi Biologics, Eli Lilly and Company og Athenex, Inc. Selskabet var tidligere kendt som Laboratorios Almirall, S.A. og skiftede navn til Almirall, S.A. i maj 2009. Almirall, S.A. blev grundlagt i 1943 og har hovedkontor i Barcelona, Spanien.
| Navn | ALMIRALL |
| CEO | Carlos Gallardo Piqué |
| Hjemsted | Barcelona,
ct Spanien |
| Websted | |
| Sektor | Sundhed |
| Branche | Lægemidler |
| Børsnotering | 20.06.2007 |
| Medarbejdere | 2.108 |
Tickersymboler
| Børs | Symbol |
|---|---|
Bme | ALM.MC |
Pnk | LBTSF |
Frankfurt | E2Z.F |
Düsseldorf | E2Z.DU |
Madrid | ALM.MC |
London | 0O9B.L |
München | E2Z.MU |
Wien | ALM.VI |